2009 H1N1 Influenza Pandemic

Woo, Teri Moser

doi:10.1016/j.pedhc.2010.05.001

Cited by 6 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although many efforts have been focused on the discovery and development of chemotherapeutic drugs, due to the antigenic determinant variations and emergence of resistant viruses, influenza virus infection has not been completely controlled and continues to be major concern and burden to public health (Woo, 2010). Therefore, the development of safe and effective anti-influenza virus drugs is still needed.…”

Section: Resultsmentioning

confidence: 99%

Protective effect of a polyphenolic rich extract from Magnolia officinalis bark on influenza virus-induced pneumonia in mice

Cai

et al. 2011

Journal of Ethnopharmacology

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Protective effect of a polyphenolic rich extract from Magnolia officinalis bark on influenza virus-induced pneumonia in mice

Cai

et al. 2011

Journal of Ethnopharmacology

View full text Add to dashboard Cite

“…In March, 2009, a new influenza virus, A(H1N1), appeared in Mexico and rapidly spread to several countries [1]. The first French cases were identified on May 1, in travelers returning from Mexico.…”

Section: Introductionmentioning

confidence: 99%

Pandemic Influenza (A/H1N1) Vaccine Uptake among French Private General Practitioners: A Cross Sectional Study in 2010

et al. 2012

View full text Add to dashboard Cite

BackgroundIn July, 2009, French health authorities, like those in many other countries, decided to embark on a mass vaccination campaign against the pandemic A(H1N1) influenza. Private general practitioners (GPs) were not involved in this campaign. We studied GPs’ pandemic vaccine (pvaccine) uptake, quantified the relative contribution of its potential explanatory factors and studied whether their own vaccination choice was correlated with their recommendations to patients about pvaccination.Methodology/Principal FindingsIn this cross-sectional telephone survey, professional investigators interviewed an existing panel of randomly selected private GPs (N = 1431; response rate at inclusion in the panel: 36.8%; participation rate in the survey: 100%). The main outcome variable was GPs’ own pvaccine uptake. We used an averaging multi-model approach to quantify the relative contribution of factors associated with their vaccination. The pvaccine uptake rate was 61% (95%CI = 58.3–63.3). Four independent factors contributed the most to this rate (partial Nagelkerke’s R2): history of previous vaccination against seasonal influenza (14.5%), perception of risks and efficacy of the pvaccine (10.8%), opinions regarding the organization of the vaccination campaign (7.1%), and perception of the pandemic's severity (5.2%). Overall, 71.3% (95%CI = 69.0–73.6) of the participants recommended pvaccination to young adults at risk and 40.1% (95%CI = 37.6–42.7) to other young adults. GPs’ own pvaccination was strongly predictive of their recommendation to both young adults at risk (OR = 9.6; 95%CI = 7.2–12.6) and those not at risk (OR = 8.5; 95%CI = 6.4–11.4).Conclusions/SignificanceThese results suggest that around 60% of French private GPs followed French authorities’ recommendations about vaccination of health care professionals against the A(H1N1) influenza. They pinpoint priority levers for improving preparedness for future influenza pandemics. Besides encouraging GPs' own uptake of regular vaccination against seasonal influenza, providing GPs with clear information about the risks and efficacy of any new pvaccine and involving them in the organization of any future vaccine campaign may improve their pvaccine uptake.

show abstract

“…Unfortunately, our interpretation is limited by the absence of data on the reasons for the patients' return visits to the clinic including the roles that media coverage may have played. However, previous research noted that up to 73% of patients that showed up at ED for H1N1 influenza fear were the "worried well" and that over 95% of the presenting concerns were minor or nonexistent [20].…”

Section: Discussionmentioning

confidence: 97%

“…report of morbidity and mortality during the pandemic [19]. In contrast, researchers have also noted that up to 73% of patients that showed up at ED for H1N1 influenza fear were the "worried well" and that over 95% of the presenting concerns were minor or nonexistent [20].…”

Section: Ojphimentioning

confidence: 99%

Model-Based Recursive Partitioning of Patients’ Return Visits to Multispecialty Clinic During the 2009 H1N1 Pandemic Influenza (pH1N1)

Mgbere

Khuwaja

2020

OJPHI

View full text Add to dashboard Cite

Background During the 2009 H1N1 influenza pandemic (pH1N1), the proportion of outpatient visits to emergency departments, clinics and hospitals became elevated especially during the early months of the pandemic due to surges in sick, ‘worried well’ or returning patients seeking care. We determined the prevalence of return visits to a multispecialty clinic during the 2009 H1N1 influenza pandemic and identify subgroups at risk for return visits using model-based recursive partitioning. Methods This was a retrospective analysis of ILI-related medical care visits to multispecialty clinic in Houston, Texas obtained as part of the Houston Health Department Influenza Sentinel Surveillance Project (ISSP) during the 2009 H1N1 pandemic influenza (April 2009 – April 2010). The data comprised of 2680 individuals who made a total of 2960 clinic visits. Return visit was defined as any visit following the index visit after the wash-out phase prior to the study period. We applied nominal logistic regression and recursive partition models to determine the independent predictors and the response probabilities of return visits. The sensitivity and specificity of the outcomes probabilities was determined using receiver operating characteristic (ROC) curve. Results Overall, 4.56% (Prob. 0.0%-17.5%) of the cohort had return visits with significant variations observed attributed to age group (76.0%) and type of vaccine received by patients (18.4%) and Influenza A (pH1N1) test result (5.6%). Patients in age group 0-4 years were 9 times (aOR: 8.77, 95%CI: 3.39-29.95, p<0.0001) more likely than those who were 50+ years to have return visits. Similarly, patients who received either seasonal flu (aOR: 1.59, 95% CI 1.01-2.50, p=0.047) or pH1N1 (aOR: 1.74, 95%CI: 1.09-2.75, p=0.022) vaccines were about twice more likely to have return visits compared to those with no vaccination history. Model-based recursive partitioning yielded 19 splits with patients in subgroup I (patients of age group 0-4 years, who tested positive for pH1N1, and received both seasonal flu and pH1N1 vaccines) having the highest risk of return visits (Prob.=17.5%). The area under the curve (AUC) for both return and non-return visits was 72.9%, indicating a fairly accurate classification of the two groups. Conclusions Return visits in our cohort was more prevalent among children and young adults and those that received either seasonal flu or pH1N1 or both vaccines. Understanding the dynamics in care-seeking behavior during pandemic would assist policymakers with appropriate resource allocation, and in the design of initiatives aimed at mitigating surges and recurrent utilization of the healthcare system. Keywords: Model-based recursive partitioning, subgroup analysis, Influenza-like-illness, H1N1, influenza pandemic, care-seeking behavior, return visit

show abstract

2009 H1N1 Influenza Pandemic

Cited by 6 publications

References 6 publications

Protective effect of a polyphenolic rich extract from Magnolia officinalis bark on influenza virus-induced pneumonia in mice

Protective effect of a polyphenolic rich extract from Magnolia officinalis bark on influenza virus-induced pneumonia in mice

Pandemic Influenza (A/H1N1) Vaccine Uptake among French Private General Practitioners: A Cross Sectional Study in 2010

Model-Based Recursive Partitioning of Patients’ Return Visits to Multispecialty Clinic During the 2009 H1N1 Pandemic Influenza (pH1N1)

Contact Info

Product

Resources

About